![New_Gilead_image](https://pharmaphorum.com/wp-content/uploads/2022/08/New_Gilead_image.jpg)
Gilead claims first CAR-T approval for leukaemia in older ad...
Gilead Sciences' Kite Pharma unit has carved out a niche for its CD19-targeted CAR-T therapy Tecartus in acute lymphoblastic leukaemia (ALL) in Europe, free of direct competition from arch-